Skip to content

CalAmp CAMP Stock-Based Comp

Stock-Based Comp at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$43.28M+45.6%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$8.75M+29.6%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$6.96M+72.4%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$3.65M-25.2%
Polaryx Therapeutics, Inc.
 logo
Polaryx Therapeutics, Inc. PLYX
$467K-89.5%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$5.55M+68.4%

Other financials

Income statement

See full
Revenue$1.3M+50.8%
Operating income-$13.1M+0.2%
Net income-$18.3M-47.4%
EPS (diluted)-$0.32+48.4%

Balance sheet

See full
Cash & equivalents$100.8M+97.9%
Total debt$2.1M-73.2%
Total equity$30.9M-40.1%
Total assets$105.5M+68.0%

Cash flow

See full
Operating cash flow-$11.0M+23.1%
CapEx--100%
Free cash flow-$11.0M+24.6%

Valuation

See full
Market cap$226.92M+666%
Enterprise value$128.2M-3,860%
P/S57.7×+47.8×

Profitability

See full
Operating margin-1,335.2%-512pp
Net margin-2,193.7%-581pp
FCF margin-1,254%

Returns & leverage

See full
Return on equity-209.3%
Debt / equity0.1×-0.1×
Current ratio6.1×-1.9×

Where this comes from

Reported directly by CalAmp in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: CalAmp’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CalAmp's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CalAmp's stock-based comp?
CalAmp (CAMP) reported stock-based comp of $1.47M in Q1 2026.
How has CalAmp's stock-based comp changed year-over-year?
CalAmp's stock-based comp increased by 71.0% year-over-year, from $861K to $1.47M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.